The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
about
Efficacy and safety of febuxostat in elderly female patients.Long-term inhibition of xanthine oxidase by febuxostat does not decrease blood pressure in deoxycorticosterone acetate (DOCA)-salt hypertensive ratsPharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjectsFebuxostat: drug review and update.Therapeutic approaches to chronic hyperuricemia and gout.Urate-lowering therapy: current options and future prospects for elderly patients with gout.Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout.Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease.Managing Gout Flares in the Elderly: Practical Considerations.A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
P2860
Q34154666-97B1B077-07CF-43AE-B57D-9010CA25B6A5Q34581053-2222D850-FF4C-47C3-AA75-381E812905F5Q36029222-DA8F10D9-9F3B-44D4-905E-02632D8A8995Q38200657-DFC6840B-BDD8-4939-A9E1-8AFC07A22DC8Q38201666-B3AE29EE-71DC-4397-A8B5-035547FE1F44Q38254304-EEC62A13-EAAE-4283-96E7-452070545817Q38365938-3D704539-7BF0-40AA-B5D6-240CD61BC11BQ38853112-7BCBF2B9-D9C9-45BF-AE0E-4A7F5073AADCQ39278948-7E4C239F-A7BF-49FF-A37A-D9E39417AFB1Q47690427-ED4F6DF1-C81D-4E6C-942D-E93B6B312753Q48162817-73F4E9DE-36CF-45EB-8545-77E20019A975Q53491436-639FCB43-A268-4AA2-BAE8-7097B17CE9E1
P2860
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The efficacy and safety of feb ...... out patients ≥65 years of age.
@ast
The efficacy and safety of feb ...... out patients ≥65 years of age.
@en
The efficacy and safety of feb ...... out patients ≥65 years of age.
@nl
type
label
The efficacy and safety of feb ...... out patients ≥65 years of age.
@ast
The efficacy and safety of feb ...... out patients ≥65 years of age.
@en
The efficacy and safety of feb ...... out patients ≥65 years of age.
@nl
prefLabel
The efficacy and safety of feb ...... out patients ≥65 years of age.
@ast
The efficacy and safety of feb ...... out patients ≥65 years of age.
@en
The efficacy and safety of feb ...... out patients ≥65 years of age.
@nl
P2093
P2860
P356
P1433
P1476
The efficacy and safety of feb ...... out patients ≥65 years of age.
@en
P2093
Barbara Hunt
Patricia A MacDonald
Robert L Jackson
P2860
P2888
P356
10.1186/1471-2318-12-11
P577
2012-03-21T00:00:00Z
P5875
P6179
1029594465